Birgid Markiefka
About
In The Last Decade
Birgid Markiefka
19 papers receiving 311 citations
Peers
Comparison fields: 5 of 43
- Oncology 144
- Epidemiology 128
- Infectious Diseases 101
- Cancer Research 65
- Molecular Biology 58
Countries citing papers authored by Birgid Markiefka
This map shows the geographic impact of Birgid Markiefka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Birgid Markiefka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Birgid Markiefka more than expected).
Fields of papers citing papers by Birgid Markiefka
This network shows the impact of papers produced by Birgid Markiefka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Birgid Markiefka. The network helps show where Birgid Markiefka may publish in the future.
Co-authorship network of co-authors of Birgid Markiefka
This figure shows the co-authorship network connecting the top 25 collaborators of Birgid Markiefka. A scholar is included among the top collaborators of Birgid Markiefka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Birgid Markiefka. Birgid Markiefka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 10 | |
| 2 | 14 | |
| 3 | 19 | |
| 4 | 70 | |
| 5 | 2 | |
| 6 | 1 | |
| 7 | 47 | |
| 8 | 5 | |
| 9 | 14 | |
| 10 | 5 | |
| 11 | 1 | |
| 12 | 21 | |
| 13 | 10 | |
| 14 | 38 | |
| 15 | 9 | |
| 16 | 8 | |
| 17 | 6 | |
| 18 | (68)Ga-DotaTATE PET-CT followed by Peptide Receptor Radiotherapy in combination with capecitabine in two patients with Merkel Cell Carcinoma. | 19 |
| 19 | 16 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.